Natural Investments LLC Has $835,000 Stake in Haleon PLC Sponsored ADR $HLN

Natural Investments LLC reduced its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 48.2% in the 2nd quarter, Holdings Channel reports. The fund owned 89,579 shares of the company’s stock after selling 83,397 shares during the quarter. Natural Investments LLC’s holdings in Haleon were worth $835,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of HLN. Morgan Stanley lifted its holdings in shares of Haleon by 16.0% during the 4th quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock valued at $217,318,000 after purchasing an additional 2,962,856 shares in the last quarter. Norges Bank acquired a new stake in Haleon during the 4th quarter worth approximately $163,529,000. Arrowstreet Capital Limited Partnership raised its holdings in Haleon by 82.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 14,674,518 shares of the company’s stock worth $146,892,000 after buying an additional 6,647,329 shares during the period. Bank of America Corp DE lifted its stake in Haleon by 116.7% in the second quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after buying an additional 6,669,923 shares in the last quarter. Finally, Sculptor Capital LP lifted its stake in Haleon by 5.1% in the fourth quarter. Sculptor Capital LP now owns 10,454,868 shares of the company’s stock valued at $105,699,000 after buying an additional 505,000 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Price Performance

Shares of HLN opened at $10.09 on Wednesday. The stock has a market capitalization of $44.38 billion, a P/E ratio of 25.87, a P/E/G ratio of 2.01 and a beta of 0.12. Haleon PLC Sponsored ADR has a twelve month low of $8.65 and a twelve month high of $11.28. The company has a 50 day moving average of $9.85 and a 200-day moving average of $9.78. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38.

Haleon Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, September 17th. Stockholders of record on Friday, August 14th will be given a $0.0642 dividend. This represents a dividend yield of 132.0%. The ex-dividend date of this dividend is Friday, August 14th. Haleon’s payout ratio is currently 30.77%.

Analysts Set New Price Targets

HLN has been the subject of several research analyst reports. Zacks Research upgraded shares of Haleon from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research note on Monday, August 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Finally, Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.